VEEV benefits from RTSM traction with major pharma wins, strengthening its clinical software strategy and long-term R&D growth outlook.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Veeva Systems (VEEV) closed the most recent trading day at $156.33, moving 1.94% from the previous trading session.
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
VEEV is expanding partnerships, growing Vault CRM adoption and boosting AI capabilities with its Ostro acquisition.
Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $167.29, denoting a -2.28% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
One of the software long bets the legendary ‘Big Short' trader Michael Burry unveiled on April 13, Veeva Systems (NYSE: VEEV), appears poised to generate exceptional short-term gains for the famed investor and most of its other shareholders.
Veeva Systems' stock is soaring upon news that it will soon join the benchmark index.
The latest trading day saw Veeva Systems (VEEV) settling at $158.49, representing a -1.22% change from its previous close.